A possible HIV/AIDS vaccine has been developed by an Ontario professor, Dr. Chil-Yong Kang. The vaccine has already been clinically tested on animals with no adverse effects or safety risks, and is now being prepped for human testing.
Kang is awaiting approval from the US Food and Drug Administration (FDA) to test the vaccine on fifty HIV positive human patients.
The testing will happen in two phases, the first to determine the safety of the SAV001-H vaccine and the second to determine the response that the vaccine stimulates.
Sumagen Canada Inc, a subsidiary of a Korean drug research company, says it is prepared to start a clinical trial for the vaccine as soon as the FDA gives its approval, and seventy countries around the world have already patented the vaccine.
Kang believes that if the trials are successful, the vaccine will be ready in about five years.